Skip to main content
. 2014 Jun 2;5(12):4071–4086. doi: 10.18632/oncotarget.1705

Figure 6.

Figure 6

The viability of GIST882, GIST48, and GIST430 cells treated with MLN8237 (MLN) in combination with imatinib (IM) for six days was measured with the TACS™ MTT cell proliferation assay (expressed as a percentage of viability under controlled culture conditions). All data represent the mean ± SD of three independent experiments. *A combination index (CI) < 1.0 indicates a synergistic effect.